Moody's Baa1, S&P BBB+ Ratings Pave Way for Sun Pharma's $11.75B Organon Acquisition

The Quick Take

• Moody's assigned Baa1 and S&P assigned BBB+ long-term ratings to Sun Pharma for its $11.75B Organon acquisition
• Investment-grade credit ratings signal agency confidence in Sun Pharma's post-acquisition financial stability
• The Organon deal would substantially expand Sun Pharma's revenue base and global geographic footprint

Sun Pharmaceutical Industries received investment-grade credit ratings from both Moody's (Baa1) and S&P (BBB+) ahead of its proposed $11.75 billion acquisition of US-based Organon and Co. The dual rating actions mark a pivotal step in deal financing, confirming that global credit markets view the combined entity as financially stable post-close. Organon, a women's health and biosimilar drug specialist spun off from Merck in 2021, contributes a meaningful earnings stream that underpins the agencies' comfort with Sun Pharma's leverage profile.

The Baa1 and BBB+ ratings grant Sun Pharma access to investment-grade bond markets at significantly lower spreads than high-yield financing, reducing the all-in cost of the $11.75 billion consideration and improving deal accretion for Sun Pharma shareholders. Rival Indian pharma majors — Dr. Reddy's Laboratories, Cipla, and Lupin — face a competitive reset as a combined Sun Pharma-Organon entity would command an entirely new scale of global commercial infrastructure. Organon's US biosimilar portfolio also adds a high-margin revenue stream that Indian generics peers currently lack.

Watch for the deal completion timeline and regulatory clearance from the US FTC and EU competition authorities, as any delay adds refinancing risk on bridge facilities. The macro variable determining deal success is US pharmaceutical pricing policy: a hostile CMS drug price negotiation environment for Organon's legacy brands could erode the revenue assumptions embedded in the agencies' ratings. Sun Pharma's next earnings release will reveal management's integration cost estimates and synergy targets for the combined group.

Synthesized from 1 source.